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We read with great interest the letter of Sodemann et al.1 on
successful treatment of a patient with refractory absence status
epilepticus (ASE) with lacosamide (LCM). In particular, Sodemann
et al. reported the case of a 64-year-old male with juvenile absence
epilepsy (he was on 400 mg/day lamotrigine, 400 mg/day topir-
amate and 2500 mg/day levetiracetam; plasma concentrations were
not investigated) and an ASE treated with intravenous (IV) diazepam
(10 mg, rapid but short lasting effect), IV levetiracetam (1000 mg,
transient effect with ASE reoccurring after 3 h), and, ﬁnally, IV LCM
(400 mg over a period of 30 min, complete recovery less than 2 h
later). LCM was considered effective in this case. We recently
reported the ﬁrst episode of a treatment of ASE with IV lacosamide.2
The patient was already on large doses of levetiracetam (3000 mg/
day, plasma levetiracetam was 25 mg/L, range 10–37 mg/L) and
valproate (2000 mg/day, plasma valproate was 87 mg/L, range 50–
100 mg/L), and had only a partial response to IV 20 mg diazepam.
Unfortunately 400 mg of IV LCM was not effective (plasma LCM after
infusion was 8.2 mg/L, range 1–10 mg/L) in the termination of the
status epilepticus (after 24 h ASE spontaneously resolved).
Is LCM effective or ineffective in ASE?
There are different criteria for the effectiveness of an antiepi-
leptic drug in the termination of status epilepticus in the literature.3
The most common speciﬁcation was termination of seizures within
30 min of infusion; nevertheless, other deﬁnitions include 3 min,
15 min, 20 min, 1 h, 12 h, 24 h and 48 h.3 In our patient, we utilized
Treiman et al. criteria4: status epilepticus is considered aborted if ictal
patterns cease within 20 min following treatment and remain
suppressed for 40 min. According to these outcome criteria, LCM
was not effective in our case, but also in Sodemann et al. patient, and
the good outcome in these cases was probably due to the known
good prognosis of ASE.5 Nevertheless, in the light of the different
criteria for the effectiveness, a call for a deﬁnition of response to the
intervention in status epilepticus is needed.
The mechanism underlying the generation of absence seizures
is due to a oscillatory activity within a corticothalamic network
that depends on GABAergic systems, but especially T-type calcium
channels.6 LCM acts primarily by interfering with the slowly
inactivating component of voltage-gated sodium currents, and nohttp://dx.doi.org/10.1016/j.seizure.2014.11.012
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P-type). Consistent with this data, LCM should show efﬁcacy for
the treatment of focal and generalized tonic–clonic seizures, but
not against absence seizures and ASE. Moreover, in our small
experience (one patient with ASE, two patients with juvenile
absence epilepsy, and three patients with juvenile myoclonic
epilepsy; data unpublished) LCM was ineffective in the treatment
of absence seizures. It is, nevertheless, evident that randomized
controlled trials are needed to establish the therapeutic effect of
LCM in the treatment of ASE and absence seizures.
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